Finding 561218 (2024-001)

Material Weakness Repeat Finding
Requirement
I
Questioned Costs
-
Year
2024
Accepted
2025-05-21

AI Summary

  • Core Issue: The organization lacked a written procurement policy before October 2024, leading to noncompliance with federal regulations.
  • Impacted Requirements: Compliance with Title 2, Subtitle A, Chapter 2 Part 200, Subpart D, section 200.318 of the Code of Federal Regulations.
  • Recommended Follow-Up: Ensure adherence to the new procurement policy implemented in October 2024 to avoid future compliance issues.

Finding Text

Federal Agency: Department of Health and Human Services Federal Program: Research and Development Cluster Assistance Listing Number: 93.847, 93.867, & 93.103 Federal Award Identification Number and Year: Various Award Period: January 1, 2024, through December 31, 2024 Type of Finding: Other Matters Finding related to Compliance within Uniform Guidance and Material Weakness in Internal Control Over Compliance Criteria or Specific Requirement: Title 2, Subtitle A, Chapter 2 Part 200, Subpart D, section 200.318 of the Code of Federal Regulations requires organizations to have a written procurement policy that includes certain requirements as it relates to procuring goods and services using federal dollars. Condition: Prior to October 2024 the Organization did not have a written procurement policy in place that covers the requirements noted in Section 200.318 of the Code of Federal Regulations. Questioned Costs: None Context: The new policy was implemented in October 2024. Our testing concluded that the new policy covers the requirements noted in Section 200.318 of the Code of Federal Regulations. In addition, 8 of the transactions in our sample for procurement testing fall under the new policy, and we noted no instances of noncompliance in those 8 transactions. This finding is recurring solely because the new policy was not in place prior to October 2024. Cause: The new policy was being developed during 2024 Effect: Noncompliance with federal procurement requirements Repeat Finding: Yes, 2023-001 Recommendation: We recommend that the Organization follow the new policy going forward. Views of Responsible Officials and Planned Corrective Actions: There is no disagreement with the audit finding. See Corrective Action Plan prepared by the Organization.

Categories

Procurement, Suspension & Debarment Material Weakness Internal Control / Segregation of Duties

Other Findings in this Audit

  • 561216 2024-001
    Material Weakness Repeat
  • 561217 2024-001
    Material Weakness Repeat
  • 561219 2024-001
    Material Weakness Repeat
  • 561220 2024-001
    Material Weakness Repeat
  • 561221 2024-001
    Material Weakness Repeat
  • 561222 2024-001
    Material Weakness Repeat
  • 561223 2024-001
    Material Weakness Repeat
  • 561224 2024-001
    Material Weakness Repeat
  • 1137658 2024-001
    Material Weakness Repeat
  • 1137659 2024-001
    Material Weakness Repeat
  • 1137660 2024-001
    Material Weakness Repeat
  • 1137661 2024-001
    Material Weakness Repeat
  • 1137662 2024-001
    Material Weakness Repeat
  • 1137663 2024-001
    Material Weakness Repeat
  • 1137664 2024-001
    Material Weakness Repeat
  • 1137665 2024-001
    Material Weakness Repeat
  • 1137666 2024-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.867 Vision Research $726,861
93.103 Food and Drug Administration Research $202,888
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $99,801